About Partners Intelligence Log in →
Connecting Israeli Defense Tech to US Needs
Log in

Taliaz

PREDICTIX — AI clinical decision-support for mental health: antidepressant selection (pharmacogenetic) + triage/care management

Israel

Latest event found: 28 Apr 2025 · over 1 year ago · nothing in the last 12 months

Vitality Radar

Insufficient evidence
Current
6M History
Industry
Updated 7 days ago

Pillar Analysis

Presence
The analyst’s view of digital footprint. Shown for context; not part of the score.
58
Business
Dated funding, customer wins, partnerships and acquisitions made, less down rounds, litigation and regulatory action.
insufficient evidence
Innovation
Dated product launches and regulatory clearances, less products retired.
insufficient evidence
Pulse
Direction: dated events in the last 90 days against the 90 before. 50 is flat.
insufficient evidence
Capacity
Dated hiring, leadership hires, expansion and certifications, less layoffs, departures and closures.
6

Strategic Assessment

Strategic Vector

Taliaz is pursuing AI-enabled precision psychiatry through pharmacogenetic prescribing, digital triage, and clinical workflow products, with commercialization centered on partnerships in Israel and Europe. Public evidence indicates continued platform activity but limited proof of broad revenue scale or rapid organizational expansion.

Efficiency Ratio

The company appears capital- and headcount-efficient, converting a small team and grant-oriented funding base into multiple pilots and partnerships, although independently verified commercial output remains modest.

Evidence Signals

Background · older than 12 months

Leadership Hire LOW IMPACT HIGH CONF 28 Apr 2025

Dekel Taliaz and Oren Taliaz were appointed directors of Taliaz Ltd, a UK-registered entity.

View source Leeds, United Kingdom
Partnership MEDIUM IMPACT MEDIUM CONF 3 Oct 2022

Taliaz partnered with Psychiatry UK to deliver AI-driven genetic testing intended to support antidepressant selection for depression patients.

View source United Kingdom and Israel
Funding HIGH IMPACT MEDIUM CONF 3 Oct 2022

Taliaz received a $2.7 million grant from the European Union Horizon 2020 program to expand clinical research on its PREDICTIX products.

View source European Union and Israel
Partnership MEDIUM IMPACT MEDIUM CONF 1 Oct 2022

Cerba and Taliaz announced a partnership to apply AI and genetics capabilities to depression care management and personalized treatment.

View source France and Israel
Partnership MEDIUM IMPACT MEDIUM CONF 1 Oct 2022

Grounded Research at RDaSH NHS Foundation Trust announced a collaboration with Taliaz to improve mental-health care in the UK.

View source United Kingdom and Israel

About
Israeli behavioral-health AI company (HQ Petah Tikva, Israel; founded ~2015 by neuroscientist brothers Dr. Dekel Taliaz (CEO) and Oren Taliaz). Its PREDICTIX platform is a clinical decision-support tool for mental health: PREDICTIX Antidepressant uses AI over genetic, clinical and demographic data to help clinicians pick the right antidepressant first time (CE-registered; commercial in EU and Israel), and PREDICTIX Care adds AI-driven patient triage, intake, queue/resource management and automated note-taking — cutting mental-health backlog by up to ~75%. Traction includes an Israel Ministry of Health agreement (~$8M) with Maccabi HMO, plus UK (Psychiatry UK) and France (Cerba HealthCare). Defense relevance: the triage/queue-management tooling has been used to cut waiting lists in Israel's trauma centers amid the post-2023 reservist mental-health surge; center of gravity is behavioral-health decision-support software, not a treatment device.
Tags
#behavioralhealth #mentalhealth #ai #pharmacogenetics #predictix #decisionsupport #triage #depression #antidepressant #dualuse

Suggest an edit

Footer

Connecting Israeli Defense Tech to US Needs

Powered by Meschonomy

Terms Privacy Contact